Back

Residual diabetic risk: from glucose lowering to cardiovascular protection.

29 August 2022 (14:45 - 15:00)
Organised by:
Congress Presentation Part of: How to deal with residual cardiovascular risk in atherosclerotic disease? New pharmacotherapeutic options Cardiovascular Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Nikolaus Marx

RWTH University Hospital Aachen, Aachen (Germany)

4 More presentations in this session

Presentation thumbnail
Residual risk in dyslipidaemias: from statins to PCSK9 inhibitors and beyond.
Professor E. Stroes (Amsterdam, NL)
Slides Video
Presentation thumbnail
Residual inflammatory risk.
Professor W. Koenig (Munich, DE)
Slides Video
Presentation thumbnail
Residual thrombotic risk: from monotherapy to dual pathway inhibition.
Professor B. Rocca (Casamassima, IT)
Slides Video
Presentation thumbnail
How to deal with residual cardiovascular risk in atherosclerotic disease? New pharmacotherapeutic options – discussion.
Video

Access the full session

Session thumbnail
How to deal with residual cardiovascular risk in atherosclerotic disease? New pharmacotherapeutic options
Video

The Event

Event poster

ESC Congress 2022

29 August 2022 14:45 CET
You may be interested in
thumbnail
Congress Session
Meet the Experts: how to lower cardiovascular disease risk in patients with diabetes
29 August 2022
thumbnail
Congress Presentation
The evolution of Guidelines.
28 August 2022
thumbnail
Congress Session
2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes
26 August 2023
thumbnail
Congress Presentation
GLP-1 RAs: more than just glucose-lowering agents.
28 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources